Table 1.
Clinical characteristics of the 12-patient case series
| Variable | Number of Patients |
|---|---|
| Mean Age (yrs) | 62.8 ± 7.4 |
| Mean Progression-Free Survival (yrs) | 0.9 ± 0.8 |
| Mean Overall Survival (yrs) | 1.4 ± 1.0 |
| Female: Male | 4:8 |
| Presenting Symptoms | |
| Headache | 6 (50) |
| Nausea | 1 (8) |
| Memory Loss | 3 (25) |
| Weakness | 5 (42) |
| Visual Deficit | 2 (17) |
| Vomiting | 1 (8) |
| Seizure | 3 (25) |
| Systemic Metastases | 2 (17) |
| Location | |
| Left: Right | 3: 9 |
| Frontal | 4 (33) |
| Temporal | 6 (50) |
| Parietal | 2 (17) |
| Surgery | |
| Initial Surgery | 12 (100) |
| Second Surgery | 4 (33) |
| Third Surgery | 2 (17) |
| Subtotal Resection | 5 (42) |
| Gross Total Resection | 6 (50) |
| Biopsy | 1 (8) |
| SNaPshot genotyping | |
| Wildtype | 11 (92) |
| TP53, 742 C > T (Arg248Trp) | 1 (8) |
| MGMT methylated: unmethylated | 4: 7 |
| Therapy | |
| Radiotherapy | 12 (100) |
| Concurrent temozolomide | 11 (92) |
| Adjuvant temozolomide | 12 (100) |
| Mean number of adjuvant temozolomide cycles | 6.3 ± 4.0 |
| Surgery at Progression | 2 (17) |
| Radiotherapy at Progression | |
| Bevacizumab | 11 (92) |
| CCNU Salvage Therapy | 4 (33) |
| Types of Inhibitors received | |
| EGFR | 4 (33) |
| HDAC | 1 (8) |
| MTOR | 2 (17) |
| MET | 1 (8) |
| CXCR4 | 1 (8) |
| VEGF | 1 (8) |
Values are presented as the number of patients (%) unless indicated otherwise. Percentages represent the percentage within a row.